Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUMOD-ID: Individualized Dosimetry for Lutathera in Neuroendocrine Tumors
NCT06395402Phase 2Recruiting
- Sponsor
- University of Iowa
- Start
- May 2024
- Primary completion
- Dec 2029
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lutetium Lu 177 dotatate in gastroenteropancreatic neuroendocrine tumor (GEP-NET) (2 arms), sponsored by University of Iowa. Primary endpoint: Objective Response Rate. Started May 2024; status: recruiting.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
gastroenteropancreatic neuroendocrine tumor (GEP-NET)
Beyond the preview
Go deeper on NCT06395402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06395402.